12:00 AM
 | 
Sep 06, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Caldolor: Phase III data

In a double-blind, U.S. and South African Phase III trial in 185 patients undergoing orthopedic surgery, 800 mg Caldolor every 6 hours met the primary endpoint of significantly reducing pain with movement during hours 6-28 post-surgery vs. placebo. Specifically, Caldolor reduced patient-assessed pain with movement by 26% as measured...

Read the full 223 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >